M&A Deal Summary |
|
|---|---|
| Date | 2010-08-02 |
| Target | Symphony Icon |
| Sector | Life Science |
| Buyer(s) | Lexicon Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 90M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1995 |
| Sector | Life Science |
| Employees | 87 |
| Revenue | 24M USD (2020) |
Lexicon Pharmaceuticals is a bio-pharmaceutical company focused on the development of breakthrough treatments for human disease. Lexicon Pharmaceuticals was founded in 1995 and is based in The Woodlands, Texas
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Add-on Acquisition) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2010) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-30 |
Lexicon Pharmaceuticals - XERMELO
The Woodlands, Texas, United States Lexicon Pharmaceuticals's XERMELO is an approved oral therapy for carcinoid syndrome diarrhea. It targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells. XERMELO is approved in the United States, the European Union, and certain additional countries for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare condition that occurs in patients living with mNETs and is characterized by frequent and debilitating diarrhea. XERMELO targets the overproduction of serotonin inside mNET cells, providing an additional treatment option for patients suffering from carcinoid syndrome diarrhea. |
Sell | $159M |
